Detalhe da pesquisa
1.
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.
Bioorg Med Chem
; 71: 116947, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35926325
2.
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
J Med Chem
; 67(1): 774-781, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38156904
3.
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
J Med Chem
; 67(6): 4936-4949, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38477582
4.
Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis.
Chin Med J (Engl)
; 135(1): 11-19, 2022 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882622
5.
Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.
RSC Med Chem
; 13(12): 1549-1564, 2022 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545438
6.
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5â¢MTA Complex for the Treatment of MTAP-Deleted Cancers.
J Med Chem
; 65(3): 1749-1766, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35041419
7.
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
J Med Chem
; 65(14): 9678-9690, 2022 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833726
8.
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.
Nat Med
; 28(10): 2171-2182, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36216931
9.
Discovery of a Series of Pyrimidine Carboxamides as Inhibitors of Vanin-1.
J Med Chem
; 65(1): 757-784, 2022 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34967602
10.
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.
J Med Chem
; 65(4): 3123-3133, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34889605
11.
Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors.
Bioorg Med Chem Lett
; 21(23): 6941-4, 2011 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22024030
12.
Discovery of indazoles as inhibitors of Tpl2 kinase.
Bioorg Med Chem Lett
; 21(16): 4758-61, 2011 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21742493
13.
Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
PLoS One
; 15(1): e0228212, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31990961
14.
Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Bioorg Med Chem Lett
; 19(23): 6571-4, 2009 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19854649
15.
Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure.
ACS Med Chem Lett
; 8(3): 316-320, 2017 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28337323
16.
Correction to "Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure".
ACS Med Chem Lett
; 8(12): 1341, 2017 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29259759
17.
Conformation-specific inhibitors of Raf kinases.
Enzymes
; 34 Pt. B: 41-66, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-25034100
18.
Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.
J Med Chem
; 53(21): 7874-8, 2010 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-20961062
19.
Dramatic effect of solvent hydrogen bond basicity on the regiochemistry of S(N)Ar reactions of electron-deficient polyfluoroarenes.
Org Lett
; 11(24): 5662-4, 2009 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-19911788
20.
Conformation-specific effects of Raf kinase inhibitors.
J Med Chem
; 55(17): 7332-41, 2012 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-22808911